PITTSBURGH--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, has unveiled its state-of-the-art GMP cleanroom facility to manufacture its pipeline of oncolytic viruses. KaliVir has already successfully executed the inaugural manufacturing run for its lead clinical candidate, VET3-TGI.
KaliVir's GMP manufacturing facility includes a cleanroom spanning over 1,000 square feet. The facility is equipped with the iCellis 500 bioreactor, hyperstack, filtration and chromatography capabilities and is supported by KaliVir’s comprehensive quality, process development and analytical development capabilities. In addition to manufacturing its own oncolytic viruses, KaliVir has the capability to provide production services for select biotechnology companies worldwide.
"The opening of our GMP facility marks a pivotal moment in our journey to advance transformative cancer therapies,” said Steve Thorne, Ph.D., Chief Scientific Officer and founder of KaliVir Immunotherapeutics. “This state-of-the-art facility underscores our dedication to meeting the highest manufacturing standards and ensuring the seamless development of groundbreaking oncolytic viral immunotherapies from conception to the clinic. We are proud of the progress we've made and excited about the potential impact our innovative treatments can have in the fight against cancer."
About KaliVir Immunotherapeutics, Inc.
KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. The company has developed a unique vaccinia virus-based platform, Vaccinia Enhanced Template “VET” Platform, that can generate potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. VET™ platform utilizes the large transgene capacity of the vaccinia virus to deliver therapeutics matched to tumor immunophenotypes to stimulate patients’ immune systems and modify the tumor microenvironment. KaliVir’s oncolytic virus candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types. KaliVir has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic vaccinia viruses derived from the VET™ platform. In addition, Astellas entered into a world-wide exclusive license to develop and commercialize KaliVir’s initial lead clinical candidate VET2-L2 oncolytic vaccinia virus. KaliVir is currently advancing multiple therapeutic candidates toward the clinic. For more information, please visit www.kalivir.com.
